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ABSTRACT 
Adipose tissue expansion and dysfunction, which leads to obesity and related metabolic 
diseases (e.g., diabetes and hypertension) are currently the most costly challenges for public 
health, yet the mechanisms underlying adipocyte functional dysregulation have not been fully 
elucidated1. Investigation is largely hindered by the unique technical limitations associated with 
handling these large, lipid-filled fat cells. New techniques need to be developed in order to 
better understand the physiology and pathology of adipocytes. 
In Paper I, by using an adipocyte-specific reporter mouse, we proved that previously reported 
adipocyte flow cytometry techniques missed the major adipocyte population. Therefore, we 
defined several crucial cytometer settings required for large cell types that allow us to analyze 
and sort both white and brown mature adipocytes. This improved strategy is applicable to sort 
adipocytes based on size without fixation, which greatly facilitates subsequent downstream 
analyses. In combination with immunostaining, the presented approach can effectively sort 
UCP1 positive adipocytes from mouse white and brown adipose tissue. Furthermore, we 
demonstrated a heterogeneous ADRB2 expression pattern in human adipocytes, which 
confirmed the applicability of our newly developed technique to further explore other aspects 
of adipocyte identity. 
In Paper II, we developed a MAAC (membrane mature adipocyte aggregate culture) system 
as a novel, high-viability model for human mature adipocytes. With a permeable membrane 
insert sitting on top to facilitate cell aggregation and nutrition access, adipocytes cultured in the 
MAAC system maintained adipogenic properties, did not dedifferentiate and had reduced 
hypoxia. This newly developed in vitro system allows us to compare depot-specific adipocyte 
gene expression, and analyze the crosstalk between adipocytes and macrophages. In particular, 
we demonstrated that human adipocytes can be transdifferentiated to brown-like adipocytes 
under the conditions of rosiglitazone stimulation or PGC-1α overexpression. Taken together, 
we provided a versatile tool for modulating primary adipocytes, opening up numerous 
downstream applications. 
In Paper III, we revealed that a large group of mature human adipocytes express an array of 
cell cycle-specific markers indicative of a cell cycle re-entry profile, and that this is associated 
with whole-body insulin resistance. We demonstrated that insulin is a critical driver of 
adipocyte cell cycle re-entry, subsequently making them vulnerable to undergo cellular 
senescence. Our data showed that hyperinsulinemia in obese patients is associated with 
increased p16 and senescence associated β-galactosidase activity in mature adipocytes. 
Furthermore, we showed that senescent adipocytes are hypertrophic and develop a senescence-
associated secretory phenotype (SASP), defined by the secretion of IL-6, IL-8, and MCP1. 
These findings challenge the dogma that adipocytes permanently exit the cell cycle upon 
differentiation and reveals cellular senescence as a new mechanism associated with 
inflammation-related adipocyte pathology. 
In conclusion, the research within this thesis has provided important techniques for both in 
vitro adipocyte modulation and high throughput flowcytometric adipocyte analysis, supporting 
multiple downstream research applications to investigate mechanisms regulating adipocyte 
physiology and pathology. Furthermore, we demonstrated the phenomenon of cell cycle re-
entry and senescence in human mature adipocytes, thereby introducing novel insights into 
obesity and hyperinsulinemia-induced adipocyte dysfunction, suggesting potential targets for 
treating obesity-related metabolic diseases. 
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1 INTRODUCTION 
1.1 OBESITY AND ADIPOSE TISSUE 
Obesity is described as excessive fat tissue expansion that may have adverse health effects. 
Body mass index (BMI), calculated by weight-to-squared height, is the most commonly used 
parameter to determine the severity of obesity. A BMI in the range of 25 to 25,9, is defined as 
overweight, with a BMI of 30 or above classified as obese. 
 
More than being of mere cosmetic concern, obesity is a high risk factor associated with 
numerous metabolic problems, including diabetes, cardiovascular disease, and cancer 2. 
Adipose tissue, and several other organs including the liver, skeletal muscle and pancreas, are 
known to be actively involved in obesity and obesity-related metabolic abnormalities. Still, the 
fact that moderate weight loss (5%) can already improve insulin sensitivity in metabolic tissues 
and reduce plasma levels of some risk factors (such as, circulating glucose, triglyceride, and 
alanine transaminase levels) for cardiometabolic disease suggests that adipose tissue is one of 
the central organs controlling metabolic balance 3. Thus, preventing or reversing unhealthy 
obesity becomes an efficient way to counter multiple chronic metabolic disorders at the same 
time.  
 
Currently, therapeutic methods for reducing body weight in morbid obesity include exercise, 
caloric restriction, and bariatric surgery. The first two demand long term persistent efforts and 
considerable willpower, and are therefore often unsuccessful in assisting obese individuals in 
achieving significant and sustained weight loss. Bariatric surgery reconstructs the digestive 
system and reduces food intake, and in most cases induce remarkable weight loss. However, 
side effects like chronic nausea and hernias, coupled with the chance of weight regain, make 
this operation not always be the best option for lots of obese individuals. It is therefore in urgent 
need to develop new treatment strategy. As such, further studies on adipocyte biology will 
bring new insights to the mechanisms regulating metabolic homeostasis in adipose tissue, and 
eventually shed light on the crucial targets to reverse obesity-related metabolic abnormalities.  
 
Adipose tissue is made up of mature adipocytes and other types of cells including adipocyte 
progenitors (preadipocytes), stem cells, immune cells, endothelial cells, and fibroblasts. Except 
for mature adipocytes, all the other cells are collectively termed the stromal vascular fraction 
(SVF). Classically, there are two types of adipose tissue: white adipose tissue (WAT) and 
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brown adipose tissue (BAT). WAT is located in distinct regions of the body, with the most 
abundant human depots being subcutaneous abdominal and visceral omental. In humans, only 
small pockets of BAT persist into adulthood, and are mainly located in the supraclavicular 
region, the thoracic paravertebral region, along the great vessels and around solid organs like 
the adrenal gland and kidney 4-6. 
 
White adipocytes (also known as mature adipocytes or fat cells) are the primary cell type that 
makes up 90% of the volume of WAT 7. Mature adipocytes are regarded as terminally 
differentiated cells, derived initially from committed progenitors (preadipocytes). 
Preadipocytes proliferate to increase cell number. Once committed to differentiation they begin 
to express mature adipocyte-associated genes and proteins, start to accumulate lipid and 
eventually grow to become large mature fat cells 8. White mature adipocytes are characterized 
by the presence of a single large lipid droplet, with the nucleus located to the side of the cell, 
close to the plasma membrane (Fig. 1). Between the lipid and plasma membrane, there is a thin 
layer of cytoplasm containing the cell organelles. Mature adipocytes are essential for keeping 
the whole-body energy balance by storing and releasing fat. However, they also function as an 
endocrine cell, secreting cytokines into the circulation to regulate a variety of functions in other 
organs (Chapter 1.2).  
 
 
 
Figure 1. Morphology and characteristics of three types of adipocytes: brown, beige and white 
adipocytes.  
 
Brown adipocytes are specialized in energy expenditure and thermogenesis 9, 10. Brown 
adipocytes are smaller than white adipocytes, they contain multiple lipid droplets and have 
abundant of mitochondria, which allow them to convert chemical energy directly into heat. 
Brown adipocytes express high levels of uncoupling protein 1 (UCP1) (Fig. 1).  
 
Mitochondria
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Nucleus
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More recently, a third type of fat cell has been identified. Beige 11-13 or brite 14 adipocytes (Fig. 
1) are functionally similar to brown adipocytes, however, compared to the developmentally-
derived brown adipocytes, beige (brite) adipocytes are inducible, they can be reprogrammed 
and transdifferentiate from white adipocytes 12, 14, 15. Beige adipocytes have drawn a lot of 
attention as a potentially promising future therapeutic tool to increase energy expenditure and 
combat obesity. 
 
This thesis work is mainly focused on understanding mature white adipocytes and their 
physiological and pathological mechanisms that contribute to obesity. 
 
1.2 THE MUTIPLE FUNCTIONS OF WHITE ADIPOCYTES 
The primary function of white adipocytes is to serve as an energy bank to store and release 
fatty acids (FAs), as needed for maintaining whole body metabolic balance 16. Fat storage is 
mediated by a process called lipogenesis, which utilizes FAs to efficiently synthesize 
triglycerides (TGs) and store them in the lipid droplet. Fatty acid release is regulated by 
lipolysis, a process through which TGs are broken down to glycerol and FAs. The FAs released 
from adipocytes are then oxidized in the muscle and other organs for energy expenditure. Both 
lipogenesis and lipolysis are sensitive to hormones and precisely regulated by multiple 
enzymes to maintain the balance between lipid flux in and out of the adipocytes. If the lipid 
storage capacity exceeds lipid removal capacity, the consequence is increased lipid droplet size 
and adipocyte size, leading to whole body obesity 17. 
1.2.1 Lipogenesis 
Adipocyte lipogenesis mainly utilizes the fatty acids derived from circulating TGs. During the 
period of energy excess, circulating TGs that are originally synthesized in the liver and intestine 
are packaged in the form of lipoproteins and travel to WAT. In adipose tissue, TGs are first 
hydrolyzed to non-esterified fatty acids (NEFA) at the surface of capillary endothelial cells via 
the lipoprotein lipase (LPL) 18, 19. Next, NEFAs move through the endothelial lumen and are 
taken up by adipocytes through fatty acid transporters such as scavenger receptor CD36, fatty 
acid transport proteins (FATPs), fatty acid binding protein (FABPs) and caveolins 20. Aside 
from exogenous fatty acids, adipocytes also make use of glucose transported into fat cells in 
response to insulin to synthesize endogenous fatty acids through de novo lipogenesis (DNL). 
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Although not the major contributor to lipogenesis in adipocytes, DNL produces adipocyte-
specific fatty acids that are essential for regulating insulin sensitivity and energy homeostasis 
21-23. Finally, fatty acids that originate exogenously and endogenously are esterified to form 
TGs via sequential actions of multiple enzymes, and eventually join in the lipid droplet. The 
detailed steps of lipogenesis are shown in Figure 2. Insulin is one of the most influential 
hormones stimulating lipogenesis. Apart from stimulating glucose uptake to facilitate DNL, 
insulin enhances both the expression of LPL in adipocytes and the LPL activity at the 
endothelial lumen to promote lipid transfer to adipocytes 24, 25. The translocation of FATP1 and 
CD36-containing vesicles to cytoplasm membranes are also stimulated by insulin to facilitate 
fatty acid uptake 26, 27. 
 
Figure 2: Schematic representation of the lipogenesis and lipolysis processes in adipocytes. In 
lipogenesis, FFA (free fatty acids) from circulation or generated through DNL are used for synthesizing 
TGs, which are stored as lipid in adipocytes. In lipolysis, TGs are broken down to FAs and glycerol that 
are released out to circulation and oxidized in organs. ACC, acetyl-CoA carboxylase; DGAT, 
diacylglycerol acyltransferase; cAMP, cyclic adenosine monophosphate. 
 
1.2.2 Lipolysis 
Lipolysis is the biochemical pathway in which TGs in the lipid droplet are hydrolyzed to 
liberate glycerol and three molecules of FAs. This is controlled via the action of three lipases: 
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adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerol 
lipase (MGL) (Fig. 2). FAs released into the circulation can be taken up by skeletal muscle, 
brown adipocytes, liver, and kidney for mitochondrial b-oxidation to fulfill energy demands. 
Released FAs can also travel back to the liver to be used as a major source of substrate for 
producing very-low-density lipoproteins (VLDLs) 16. 
 
Adipocytes experience a basal level of lipolysis. Yet, to a large extent, lipolysis is triggered 
by hormones, such as catecholamines, cortisol and glucagon 28. Catecholamines bind b-
adrenergic receptors (ADRB) on the adipocyte plasma membrane to stimulate cAMP 
production and activate protein kinase A (PKA), resulting in the phosphorylation of the rate-
limiting enzyme HSL that initiates the lipolysis process (Fig. 2 and ref. 29). The density of 
ADRB on the adipocyte membrane is one of the essential factors that determine lipolysis rate 
30. In rodents, white and brown adipocytes express all three ADRBs (ADRB1, ADRB2, 
ADRB3) which are responsible for lipolysis and non-shivering thermogenesis 31. In human 
adipocytes, ADRB1, ADRB2 and a2 adrenergic receptor (ADRA2) are the major subtypes 
which respond to catecholamines. ADRB1 and ADRB2 promote lipolysis while ADRA2 is 
an anti-lipolytic receptor. Therefore, the balance between b and a adrenergic receptor 
determines the lipolysis rate 32, 33. More recently, the cardiac-derived natriuretic peptides 
(NPs), including atrial NP (ANP) and the B-type NP (BNP), have also been shown to be 
robust stimulators of adipocyte lipolysis in humans 34. ANP and BNP bind to the membrane 
receptor NP receptor A (NPRA) promote HSL mediated lipolysis through cGMP-dependent 
protein kinase pathway 35. Compared to catecholamine and NPs pathways, insulin acts as the 
major anti-lipolysis hormone suppressing both ATGL and HSL activation to limit lipid 
digestion 36, 37.  
1.2.3 Lipolysis in obesity 
As measured by lipid 14C dating, during the average 10 year life span of a human adipocyte 
the lipid contained within is replaced approximately 6 times, with an average age of 1.6 years 
38, 39. This indicates that adipocyte lipogenesis and lipolysis are dynamic processes 39. A 
follow-up study using the same technique on a large human cohort revealed that lipid age in 
obese individuals is significantly higher than that in non-obese ones, suggesting that lipid 
removal capacity is blunted, causing increased lipid deposition and body weight gain 17. 
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Reduced energy expenditure and, more importantly dysregulated lipolytic response, are the 
major factors limiting lipid removal rate 29, 40.  
 
Basal lipolysis. Studies on lipolysis have demonstrated that overall basal lipolysis in obese 
subjects is increased, while stimulated lipolysis is decreased 41, 42. Studies using microdialysis 
to measure the release of the lipolytic substrate glycerol reveal a higher lipolytic rate in obese 
individuals compared to lean. However, when the amount of glycerol released was 
normalized to the amount of tissue, no difference between lean and obese was observed, thus 
suggesting that it is the total fat mass that contributes to increased lipolysis in obesity and not 
intrinsic changes in the adipocytes themselves 30, 41. Furthermore, Tchernof et al. analyzed 
basal lipolytic rate in relation to adipocyte number and showed that large adipocytes release 
more glycerol than smaller ones, indicating that the observed increase in lipolysis in obese 
individuals could also be due to enlarged adipocyte size 43. 
 
Stimulated lipolysis. Although basal lipolysis is enhanced, obesity is found to be associated 
with a low rate of lipid removal, which is significantly attributed to impaired stimulated 
lipolysis 42. Catecholamine-stimulated lipolysis is largely determined by the abundance of 
ADRBs on the plasma membrane. It has been observed that b-adrenergic lipolytic 
responsiveness is impaired in obese subcutaneous adipose tissue 30. As mentioned above, 
both ADRB1 and ADRB2 are involved in the human lipolytic response. The administration 
of selective agonists of either the b1 or b2 adrenergic receptors (dobutamine and salbutamol) 
reveal no difference in ADRB1 stimulation, glycerol or FFA release in lean and obese 
animals 44. However, ADRB2-induced lipolysis significantly decreased in obese mice, 
implying that blunted ADRB2 activity is responsible for decreased adipose lipolysis in 
obesity 44. Similar results were observed in human studies, where obese individuals exhibited 
an almost 70% reduction in ADRB2 sensitivity, as measured by saturated 125I-cyanopindolol 
binding. However, ADRB1 and ADRA2 sensitivity was unchanged compared to lean 
individuals 30. This compelling data, again, emphasizes the importance of ADRB2 in 
regulating lipolysis.  
 
The studies measuring ADRB2 expression levels mentioned above were mostly performed 
at a bulk cell level, which lacks information from individual cells and is difficult to calibrate 
with adipocyte size 30. This is particularly relevant because adipocytes are known to be 
heterogenous in both size and function 45. In response to the lack of tools to efficiently analyze 
large numbers of individual adipocytes, we have developed a new flow cytometry-based 
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method to analyze adipocytes in a high throughput way and used it to detect the ADRB2 
expression in human adipocytes (Paper I). Our results demonstrated a heterogeneous 
expression of ADRB2 on human adipocytes and that decreased ADRB2 expression in obesity 
was explained by ADRB2 receptor loss in a subpopulation of adipocytes. The unexpected 
finding of an ADRB2 negative population warrants further investigation.  
1.2.4 Adipocyte endocrine functions 
Apart from serving as the lipid storage pool, adipocytes also interact with the surrounding 
environment by secreting multiple adipokines and peptides that are physiologically important 
for maintaining the metabolic balance. Collective evidence has revealed that adipocytes secrete 
more than 50 peptides involved in metabolism, immune response and extracellular matrix 
remodeling 46. The secretory list is composed of not only the dominant adipokines such as 
leptin and adiponectin, but also includes proinflammatory cytokines such as tumor necrosis 
factor α (TNF-a), monocyte chemoattractant protein 1 (MCP1) and interleukin 6 (IL-6), which 
are expressed by both adipocytes and macrophages 47. 
 
Leptin. Adipocytes are the major source of circulating leptin, which acts on leptin receptors 
present in neuron to suppress appetite and increase energy expenditure 48, 49. Through 
sympathetic nerve fibers that innervate adipocytes, leptin has been shown to suppress adipocyte 
lipogenesis and enhance lipolysis 50, 51. Mouse models of genetic disruption of leptin or the 
leptin receptor (ob/ob, db/db) result in profound body weight gain and increased food intake 52, 
53. Furthermore, the administration of recombinant leptin to humans or animals with leptin gene 
mutations induced a rapid depletion of fat mass and corrected multiple obesity related 
abnormalities 54. However, administering additional leptin to obese individuals does not have 
the same impact on body weight, as leptin resistance develops during obesity 54-57. In obesity, 
hypertrophic adipocytes secrete more leptin to compensate for the loss of sensitivity, resulting 
in increased serum leptin levels, positively correlating with the percentage of body fat in obesity 
58, 59. In turn, excessive serum leptin can induce the expression of fibroblast growth factor 2 
(FGF-2) and vascular endothelial growth factor (VEGF), which stimulates adipose tissue 
angiogenesis and increases vascular permeability, potentially alleviating hypertrophy-induced 
hypoxia 60.  
 
Adiponectin is crucial for maintaining healthy adipose tissue expansion and improving insulin 
sensitivity while enhancing lipogenesis and adipogenesis 61, 62. Administration of adiponectin 
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to mice increases fat mass but prevents ectopic lipid accumulation, thus lowering the risk of 
insulin resistance 63. Serum adiponectin levels are negatively associated with insulin resistance, 
but not with BMI, indicating an insulin-related effect on adiponectin secretion 64.  
 
Inflammatory factors. Adipocytes can secrete TNF-a, IL-6, and MCP-1, with a low expression  
in lean subjects that increases in obesity. These inflammatory factors have been shown to 
contribute to the chronic inflammation occurring in obese adipose tissue and are associated 
with impaired insulin sensitivity 65. TNF-a is a proinflammatory cytokine, influencing the 
immune response by activating the release of other proinflammatory cytokines, such as IL-6 
and IL-1β 66. TNF-a and IL-6 downregulate the expression of the adipogenic genes peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein a (C/EBPa), 
thus impeding preadipocyte proliferation and differentiation, which in turn inhibits adipose 
tissue hyperplastic expansion 67, 68. Both TNF-a and IL-6 suppress adiponectin secretion and 
inhibit expression of several mediators of the insulin signaling pathway, including insulin 
receptor substrate 1 (IRS1) and glucose transporter 4 (GLUT4) 68, 69. MCP-1 recruits 
macrophages which further secrete TNF-a, MCP-1, and other chemokines, consolidating the 
chronic inflammatory environment, in turn, driving whole body insulin resistance 70.  
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1.3 INSULIN AND INSULIN RESISTANCE IN ADIPOCYTES 
Insulin is one of the essential hormones for cell survival, growth and proliferation 71. Insulin is 
synthesized and secreted by b-cells of the pancreas in response to increases in the serum 
glucose level. The secreted insulin is delivered to target tissues and recognized by insulin 
receptors (INSR) expressed on cell plasma membranes in organs including the liver, adipose 
tissue, skeletal muscle and brain 72.  
1.3.1 Insulin signaling 
Insulin binding to the INSR triggers the recruitment and phosphorylation of intracellular insulin 
receptor substrate 1 (IRS1), which can further assemble phosphoinositide 3-kinase (PI3K) and 
phosphorylate phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3) 73. Through PIP3, the key downstream effector AKT (also known as 
protein kinase B; PKB) is translocated to the plasma membrane and phosphorylated at two sites 
for full function: Thr-308 by phosphoinositide-dependent kinase 1 (PDK1); or at Ser-473 by 
mechanistic target of rapamycin complex 2 (mTORC2) 74, 75. The phosphorylation of AKT 
activates several downstream effectors to regulate a complex metabolic program (Fig. 3). For 
example, AKT activates AS160 (also called TBC1D4) to stimulate GLUT4-mediated glucose 
uptake, AKT inactivates GSK3 (glycogen synthase kinase-3) to promote glucose storage as 
glycogen, and AKT inhibits TSC2 (tuberous sclerosis complex 2) to activate mTORC1 to 
enhance protein and lipid synthesis and stimulate cell growth 76, 77. Aside from the PI3K/AKT 
pathway, the mitogenic effect of insulin is mediated by extracellular-regulated protein kinase 
(ERK) 78, which is another insulin receptor downstream pathway responsible for cell growth, 
proliferation, and differentiation 79.  
 
Insulin in adipocytes. The crucial role of insulin in adipocytes is to promote nutrient storage, 
including inducing glucose uptake and lipid uptake, as well as stimulating DNL while 
inhibiting lipolysis (Chapter 1.2). Glucose uptake is an important action of insulin for carbon 
energy deposition, in which GLUT4 is the major transporter mediating glucose uptake. When 
serum insulin levels are low, GLUT4-containing vesicles are maintained in the cytoplasm. 
When insulin levels increase, in an immediate response, insulin-activated AKT triggers 
GLUT4 translocation to the plasma membrane to facilitate the transportation of glucose derived 
from dietary carbohydrates into adipocytes 80. The majority of glucose in adipocytes is 
transformed to glycerol, used as the backbone for TGs synthesis. Whereas, a small fraction of 
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glucose can be stored as glycogen for later energy demands, or be broken down through 
glycolysis and the tricarboxylic acid cycle to eventually be used in DNL 81. Furthermore, 
insulin is essential for adipose tissue expansion. Insulin can efficiently stimulate fatty acid 
uptake through activation of LPL, and the redistribution of fatty acid transporters CD36 and 
FATP to the cellular membrane, while inhibiting lipolysis through dephosphorylation of HSL. 
Therefore, insulin promotes lipid storage in adipocytes, which is one essential reason inducing 
adipocyte size enlargement. Fat specific insulin receptor knockout mice rapidly displayed 
lipodystrophy with profound loss of subcutaneous and visceral adipose tissue, hyperlipidemia, 
insulin resistance, and severe fatty liver disease 82. This study, supported by numerous other 
studies demonstrates the important role of insulin in adipogenesis and adipocyte growth 83-85. 
 
 
Figure 3. Schematic representation of insulin signaling pathway. The binding of insulin on the insulin 
receptor (INSR) initiates a cascade of phosphorylation events, with the two major downstream pathways 
being PI3K/AKT and Ras-Raf-MEK-ERK (MAPK/ERK) pathway. Activation of AKT regulates 
multiple metabolic effects including glucose transport, lipid and glycogen synthesis, as well as cell cycle 
progression. The MAPK/ERK pathway plays a critical role in regulation of cell proliferation.  
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1.3.2 Insulin resistance, hyperinsulinemia, and obesity 
Insulin resistance. The above-mentioned multiple insulin functions are dysregulated during 
the development of obesity, as fat cells gradually lose their insulin sensitivity and become 
insulin resistant (IR) 86. It has been shown that almost 50% of diabetic obese individuals express 
reduced INSR tyrosine kinase activity in the adipocytes 87. The AKT downstream GLUT4 
expression in adipocytes is reduced in insulin resistant obese and type 2 diabetic individuals 88. 
As such, reduced glucose uptake is considered as the most significant consequences of insulin 
resistance. The blunted insulin signaling and glucose uptake ability are attributed to high serum 
glucose. Therefore, measurement of insulin-stimulated glucose uptake is a widely used method 
to assess insulin sensitivity.  
 
Hyperinsulinemia develops in parallel with insulin resistance. Due to adipose tissue insulin 
resistance, glucose and lipid cannot be stored in adipocytes efficiently. In situations of 
excessive caloric intake, ectopic lipid accumulate in liver and muscle. This fat deposition in 
non-adipose organs is detrimental to organ health (known as lipotoxicity) and can lead to the 
loss of insulin sensitivity in these tissues and increased serum glucose. To maintain a normal 
glucose level the pancreas secretes a higher amount of insulin, referred to as hyperinsulinemia. 
If insulin resistance persists, the high production of insulin eventually results in pancreatic b-
cell exhaustion and functional failure. At this point, endogenous insulin secretion decreases. 
When the level of insulin is unable to maintain glucose homeostasis, hyperglycemia occurs and 
type-2 diabetes is diagnosed 89.  
 
Hyperinsulinemia induced obesity. It remains debated whether hyperinsulinemia drives 
obesity, or whether obesity induces hyperinsulinemia 90. Most obese individuals tend to present 
with various degrees of hyperinsulinemia, whereas others can still maintain a healthy level of 
fasting insulin, controvercially called “healthy-obese” 91. This suggests that obesity may 
develop before hyperinsulinemia. However, there is abundant evidence that supports initial 
hyperinsulinemia as the driver of obesity: meal-induced transient hyperinsulinemia already 
occur in individuals with mild glucose intolerance but who are not yet obese similar to what 
happens during a glucose tolerance test 92. This indicates the possibility that adipose tissue in 
moderately obese individuals may have already been stimulated by high levels of insulin 
occasionally. High levels of insulin facilitate lipogenesis and stimulate adipogenesis 81, leading 
to adipocyte hypertrophy and tissue expansion under conditions of nutrient excess. It has been 
observed that type 1 diabetic individuals gain significant body weight after insulin treatment, 
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which also occurs in type 2 diabetics, indicating a remarkable effect of insulin on adipose 
expansion even in insulin resistant adipose tissue 93, 94.  Furthermore, a short stimulation of 
hyperinsulinemia was shown to promote inflammation by inducing the secretion of TNF-a, 
IL-6 and MCP-1, in turn further aggravating tissue insulin resistance 95-98. Taken together, the 
evidence suggests that hyperinsulinemia, induced by nutritional overload, can occur at an early 
phase of obesity, trigger adipocyte hypertrophy and induce tissue inflammation which further 
exacerbates adipose tissue insulin resistance.  
 
Paradox of selective insulin resistance. It is well established that insulin plays a vital role in 
promoting adipocyte growth in insulin-sensitive adipocytes 81. So what happens in insulin 
resistant adipocytes, and how does hyperinsulinemia affect adipocyte function? It has been 
suggested that the insulin pathway is selectively blocked in insulin resistant adipocytes, mainly 
impairing the glucose uptake arm of insulin signaling, leaving the other side effectors of AKT 
intact 99. This data also indicates a possibility that in the presence of hyperinsulinemia, part of 
the insulin signaling pathway could even be overstimulated and potentially trigger 
hyperactivation of downstream insulin effectors such as ERK or mTORC1. This hypothesis, 
which has been explored in the liver, vasculature and brain, is referred to as the ‘paradox of 
selective insulin resistance 100-102. However, whether it also occurs in human adipocytes is still 
unclear.   
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1.4 ADIPOSE FAT MASS REGULATION IN OBESITY 
Fat mass expansion is an adaptive response of adipocytes to increase their storage capacity. 
Despite being linked to obesity, fat mass expansion is crucial for keeping metabolic balance. 
Healthy adipocytes enlarge, increasing their storage capacity, to keep excess lipids in a ‘safe’ 
manner while maintaining metabolic homeostasis. When the adipose tissue fails to expand, for 
example in medical conditions like lipodystrophy, the consequences for the individual are 
strikingly similar as those of severe obesity, namely metabolic disorders including insulin 
resistance, hepatic steatosis, hyperlipidemia and ectopic lipid accumulation in non-adipose 
organs 103, 104. Ectopic lipid accumulation is deleterious, as it can cause insulin resistance, 
cardiovascular problems and other lipotoxic outcomes 103, 105. Therefore, it is crucial to preserve 
adipose tissue for maintaining a safe lipid storage capacity. 
 
Excessive calorie intake induces adipose tissue expansion mainly through two processes: 
increasing adipocytes cell size (hypertrophy), and/or recruiting new adipocytes to increase cell 
number (hyperplasia) (Fig. 4). During weight gain, the lipid accumulation is greater than 
release and adipocytes enlarge their size to store more fat 40, 106, 107. If the calorie-overloading 
situation is not compensated for by increased energy expenditure, adipogenesis is triggered to 
expand fat cell number in response to increased storage needs 37, 108.  
1.4.1 Hyperplastic adipose expansion 
Adipogenesis is the process through which new adipocytes arise from committed preadipocytes 
(Fig. 4). The development of hypertrophic expansion activates adipogenesis, which thus relates 
to severe body weight gain 109, 110. Generally, adipogenesis is considered to be a protective and 
‘safe’ way to expand adipose tissue, as this process recruits more insulin sensitive small 
adipocytes 111-113. Obese individuals with hyperplastic adipocytes are associated with a better 
metabolic profile, as demonstrated by Arner et al. in a large cross-sectional study 114. 
Individuals who regain body weight after bariatric surgery are more insulin sensitive compared 
to body-weight matched never-obese controls. This is associated with a significantly increased 
fat cell number during body weight regain, while cell size is not changed 115. Moreover, 
rosiglitazone treatment which paradoxically increases adipogenesis and thus adipocyte 
number, significantly improves the metabolic profile of individuals. On a tissue level, 
hypertrophic adipose tissue is associated with increased levels of hypoxia, fibrosis and 
macrophage infiltration, whereas hyperplastic adipose tissue contains relatively high blood 
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vessel density and lower hypoxia and inflammation 116, 117. If adipogenesis is impaired, the 
existing adipocytes continue to uptake the lipid present in the circulation leading to adipocyte 
hypertrophy, insulin resistance and eventually ectopic fat storage 118. Therefore, at the state of 
energetic imbalance, adipose tissue hyperplasic response is healthier than a hypertrophic one. 
 
Figure 4. Schematic representation of adipose tissue expansion. Adipocyte number is determined by 
preadipocyte proliferation and adipogenesis, whereby terminally differentiated preadipocytes 
accumulate lipid and increase cell size to become mature adipocytes. Adipose tissue expansion takes 
place through hypertrophy, an increase in the cell size of existing adipocytes, with or without subsequent  
hyperplasia. 
 
Adipogenic regulation. A stable adipocyte cell number is maintained dynamically, with 
approximately 10% of human adipocytes replaced every year 38, 114. This means adipogenesis 
is continually ongoing with new adipocytes constantly being lost and generated. Despite the 
crucial importance of adipogenesis and hyperplasia, the mechanisms controlling cell number 
amplification are not fully understood. The process of adipogenesis includes two aspects: 
preadipocyte proliferation to increase their number, and the differentiation of preadipocytes to 
become fully mature fat cells. Precisely controlled adipogenesis involves the cooperation of a 
complex array of transcriptional signals, endocrine factors and hormones. Growth hormone, 
glucocorticoids and thyroid hormone promote adipogenesis. Insulin and IGF-1 are known to 
have a robust pro-adipogenic effect also.  
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A large body of cell culture and mouse model studies has broadened our knowledge of 
adipogenesis mechanisms. C/EBPa 119 and PPARγ are two master adipogenic transcription 
factors coordinating the expression of a myriad of proteins to establish the characteristics of 
mature adipocytes 118, 120. In mice, C/EBPa is essential for adipocyte terminal differentiation 
after birth, while PPARγ is required for developmental adipogenesis, both in embryogenesis 
and adulthood 121. Other transcription factors, including SREBP1c (sterol regulatory element-
binding protein), STATs (signal transducers and activators of transcription), AKT2 122 and 
PDGFRb (platelet-derived growth factor receptor β)123, have also been shown to play a 
significant role in controlling adipogenesis, however the list is still expanding. 
 
Despite this, more human studies are needed to evaluate these mechanisms proposed in animal 
models. It would be informative to understand how cell number is strictly controlled in humans, 
and in turn elucidate new aspects of fat mass control and metabolic homeostatic maintenance.  
1.4.2 Adipocyte size and hypertrophic adipose expansion 
When overnutrition exceeds adipose storage capacity, the lipid deposited in non-adipose organs 
is considered a significant driving force causing insulin resistance and obesity related metabolic 
disorders 103. This “limited expandability hypothesis” emphasizes that both adipocyte size and 
number can reach saturation points of maintained healthy expansion. Adipocyte size is 
particularly crucial for determining adipose tissue homeostasis, as hypertrophic adipocytes 
have been widely recognized as the primary component of obesity-related metabolic syndrome 
111. 
 
1.4.2.1 Hypertrophic adipocytes 
The association between adipose tissue hypertrophy and metabolic dysregulation has been 
intensively explored. A short-term overfeeding study revealed that a 3kg increase in body 
weight in moderately obese individuals resulted in a 10% adipocyte size enlargement 106. 
Adipocyte hypertrophy is a high risk factor predicting impeded insulin sensitivity 106. A large 
cohort study of 764 non-obese and obese subjects demonstrated that adipocyte hypertrophy is 
an independent factor correlating with circulating insulin levels. In this study, female subjects 
with a large fat cell volume relative to BMI matched individuals exhibited multiple adverse 
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metabolic profiles, such as decreased insulin sensitivity and increased circulating cholesterol 
and triglycerides levels 114. 
 
Human mature adipocyte size varies greatly, with a broad range from 20 µm to 300 µm in 
diameter. Generally, an adipocyte with a diameter less than 70 µm is considered a small 
adipocyte, while 70 µm-120 µm is large, and adipocytes over 120 µm are considered very large 
124. Compared to small adipocytes, large fat cells display distinct transcription profiles, in which 
the major alteration is an overactivated immune and inflammatory response 125, demonstrated 
by a large body of transcriptomic studies (reviewed in ref.126). Skurk et al. have separated 
adipocytes based on a similar size category mentioned above and revealed that the larger 
adipocytes secreted increased levels of IL-6, IL-8, MCP-1 and leptin, supporting the role of 
hypertrophic adipocytes in their contribution to adipose tissue inflammation 127. Moreover, 
hypertrophic adipocytes show reduced insulin sensitivity 128. In a study that compared small 
versus large adipocytes from matched individuals, Western blot analysis from an equal volume 
of cells revealed no difference in insulin receptor or GLUT4 expression 129. However, insulin-
stimulated GLUT4 translocation to the plasma membrane was increased two fold in small cells 
versus large cells, implying that insulin-GLUT4 signaling is impaired in hypertrophic 
adipocytes 129, 130. Together, these data illustrate multiple functional alterations in large fat cells 
which are crucial contributors to adipose tissue metabolic dysfunction. 
 
1.4.2.2 Mechanisms regulating adipocyte size 
Despite the importance of cell size alterations, the mechanisms regulating adipocyte size are 
still under investigation. Several hypotheses have been proposed to explain adipocyte 
hypertrophy. Firstly, adipocyte size expansion is determined by lipogenic capacity, whereby 
the lipid availability and adipocyte lipid uptake capacity are vital components 131-133. Moreover, 
recent studies in mice reported that adipocytes utilize ion channels to create a hypotonic 
environment to facilitate cell swelling. Two proteins, transient receptor potential cation channel 
subfamily V member 4 (TRPV4) 134 and SWELL1 (VRAC, voltage-regulated anion 
channel)135 were recognized as crucial regulators controlling hypotonic or hypertonic pressure, 
inducing cell size alteration and mediating GLUT4 membrane translocation. Furthermore, 
caveolae, the bulb-shaped surface pits located on the adipocyte plasma membrane, are also 
important for regulating GLUT4 translocation 136. Caveolae can also function as a sensor of 
mechanical and osmotic stress, and therefore coordinate the alteration of cell size 137. 
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So far, the consequences of altering cellular mechanical morphology have largely focused on 
glucose uptake, though this likely does not explain all the functional changes in hypertrophic 
fat cells. Notably, although cell enlargement is significantly associated with increased lipid 
droplet size, it also translates into higher cellular demands, in that cells require a larger 
cytoplasm with more organelles to produce enough transcripts and proteins to support regular 
cellular function 138, 139. For example the production of perilipin, a lipid droplet-associated 
protein, needs to increase to maintain the integrity of the lipid droplet membrane. Similarly, 
large adipocytes need more cytoskeleton to keep efficient intracellular trafficking, preserve 
cellular integrity and avoid cell breakage 140. Indeed, the total number of transcripts produced 
in large adipocytes has been shown to be increased compared to small cells 138. However, it is 
still not clear how adipocytes adapt to this growth demand. It is also not clear whether this can 
be driven by overloaded growth stimuli such as insulin, IGF-1 (insulin-like growth factor 1) 
and others. 
 
1.4.2.3 The mTOR pathway in cell growth 
The mechanistic target of rapamycin (mTOR), and especially mTOR complex 1 (mTORC1), 
is a highly conserved effector regulating cell growth in all eukaryotes and is suggested to be 
involved in adipocyte size regulation 141, 142. Insulin and IGF-1 activate mTORC1 through the 
phosphorylation of AKT to inhibit the mTORC1 negative regulator, TSC (Fig. 3). Feeding-
induced amino acid levels can also activate mTORC1, which is sensed by the heterodimeric 
Rag GTPases 143. As a result, mTORC1 activates downstream substrates p70S6 Kinase 1 
(S6K1) and eIF4E Binding Protein (4EBP) to promote protein synthesis, de novo lipid 
synthesis for plasma membrane expansion, and nucleotide synthesis required for DNA 
replication 142.  
 
The mTOR pathway is activated in obese adipose tissue 144, 145. Hyperinsulinemic rats, 
maintained by chronic insulin-containing pumps, developed insulin resistance 146. 
Interestingly, the liver and muscle from these rats showed impaired insulin signaling, while the 
adipose tissue was unaffected, showing preserved pAKT and mTORC1/S6K expression 146. 
Additionally, mTORC1 deactivation via adipocyte-specific Raptor knockout resulted in 
lipodystrophy and ectopic lipid deposition in the liver, suggesting a crucial role of mTORC1 
in regulating adipose expansion via affecting both size and adipogenesis 147. Furthermore, 
metformin, as the first-line anti-diabetic drug, inhibits mTORC1 via activation of adenosine 
monophosphate-activated protein kinase (AMPK). Metformin significantly promotes insulin 
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sensitivity and reduces fat mass in obese insulin-resistant children 148. Moreover, treatment 
with metformin and the mTORC1 inhibitor rapamycin, revealed a profound anti-inflammatory 
profile through inhibition of NF-κB (nuclear factor-kappa beta) 149, 150, suggesting that the 
mTORC1 pathway could potentially regulate both adipocyte growth and inflammation, in line 
with our results (Paper III).  
 
1.4.3 Cell cycle related growth 
High levels of insulin, growth factors and some hormones can be strong growth stimulators, 
known to induce cell enlargement and proliferation 151-155. Terminally differentiated mature 
adipocytes, with their large lipid droplet, are traditionally considered as postmitotic cells. How 
adipocytes react to such strong growth stimuli remains poorly examined and not fully 
understood.  
 
Interestingly, it has been demonstrated that apparently postmitotic neurons can also adopt a cell 
cycle-like profile, expressing multiple cell cycle related cyclins and proteins 156. Neuron cell 
cycle re-entry seems to be dependent on the activation of the mTOR pathway but has been 
linked to cell death in Alzheimer's disease and other neuronal degeneration disorders 157-160. 
Whether adipocytes can also be stimulated to re-enter a cell cycle program in the presence of a 
mitogenic stimuli is in investigated here (Paper III), and we demonstrated that adipocytes 
exhibited an endoreplication profile, rather than a mitotic cell cycle (Fig. 5). 
 
1.4.3.1 Endoreplication 
Endoreplication, where cells proceed through the cell cycle without division, has recently been 
proposed to be an important mechanism coordinating cellular proliferation and differentiation 
161. Endoreplicating cells move through the G1, S, and G2 phases, increasing cell size and 
replicating their DNA (Fig. 5). In the absence of cytokinesis, the cell either skips mitosis 
resulting in a polyploid mononuclear cell, or proceeds through mitosis with nuclei division 
giving rise to multi-nucleated cells 162. Increased DNA content allows cells to enhance their 
capacity to produce transcripts and proteins to permit cell growth, and facilitates nutritional 
storage and transportation 161. Therefore, endoreplication usually occurs in terminally 
differentiated cells, and is considered an advantageous strategy for cells adapting to continuous 
growth. In the absence of cytokinesis, endoreplication does not involve cytoskeletal 
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rearrangement, and unlike mitotic division, causes less disruption to highly structured tissues 
163.  
 
 
Figure 5. Schematic representation of mitotic cell cycle and endoreplication. A mitotic cell goes through 
4 phases of cell cycle, passing through M-phase, undergoing cytokinesis and becoming two daughter 
cells. Endoreplicating cells replicate DNA, although they do not pass through M-phase (endomitosis) 
or pass through M-phase but fail to undergo cytokinesis. 
 
While endoreplication has been investigated extensively in worms and flies 164, its role in 
human cells is attracting increasing attention. Megakaryocytes are known for endoreplicating 
before fragmenting into platelets. Furthermore, hepatocytes, trophoblast giant cells, and 
mammary epithelial cells are also reported to undergo endoreplication to support their 
specialized functions 165-167. In particular, hepatocyte endoreplication was found to be induced 
by insulin through PI3K/AKT pathway, implying an important role of insulin in regulating cell 
growth via endoreplication 154. Whether this mechanism also occurs in human adipocytes was 
still not clear. Addressing this question will potentially provide new insights into adipocyte 
hypertrophy and related functional regulation. 
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1.4.3.2 Cell cycle data in adipocytes 
Several studies have observed the expression of cell cycle related proteins in mature adipocytes. 
For example, the expression of cyclin proteins (D1, E1, A2, and B1) are well known to drive 
cell cycle progression, through the formation of complexes with their corresponding cyclin 
dependent kinases (CDKs) to regulate a myriad of substrates. CDK4/Cyclin D complex, which 
phosphorylates retinoblastoma protein (RB) to initiate cell cycle entry and support progression 
of G1 to DNA synthesis 168, has been observed in adipocytes. Lagarrigue et al. show the 
expression of cyclin D3 and CDK4 in mature adipocytes in both mice and humans, but suggest 
that these perform cell cycle independent roles. Their study found that CDK4 phosphorylates 
IRS-2 to activate the insulin pathway. Secondary to promoting insulin sensitivity, CDK4 
activity induced lipogenesis and inhibited lipolysis, leading to increased fat mass and adipocyte 
hypertrophy  169. This evidence suggests an insulin-induced adipocyte growth mechanism that 
is associated with cell cycle-related proteins. Consistently, cyclin D1 expression has also been 
shown to be upregulated in adipocytes that differentiated in vitro 170. However, examination of 
in vivo expression by analyzing adipose tissue sections has not revealed cyclin D1 expression 
in mature adipocytes 170.  
 
Ki-67 is a well-established proliferation marker expressed in all phases of an active cell cycle, 
except for the G0 phase or cell-cycle arrested cells 171. Two different studies used mouse 
models to investigate the expression of Ki-67 in white and brown adipocytes, supporting the 
hypothesis of adipocyte proliferation 172, 173. However, these studies examined only adipose 
tissue sections, where distinguishing adipocytes and cells from the SVF is not straightforward 
and raises questions about the specificity of the observed Ki-67 signal.  
 
In order to investigate these fundamental questions of adipocyte biology, in Paper III, we used 
sensitive quantification methods that specifically focus on a pure population of mature 
adipocytes. By showing the expression of multiple cyclins (D1, E1, and A2), and cell cycle 
related proteins, including pHH3, PCNA (proliferating cell nuclear antigen), Ki-67, and 
Anillin, we demonstrated a cell cycle profile occurred in human mature adipocytes, indicated 
a potential link between adipocyte cell cycle re-entry and hypertrophy. 
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1.5 CELLULAR SENESCENCE 
Hypertrophic adipocytes display an augmented secretion profile in obesity, which is one of the 
detrimental driving forces in adipose tissue inflammation, insulin resistance and obesity-related 
pathologies. However, the mechanisms underlying adipocyte size enlargement and 
proinflammatory secretion are still elusive 127. Senescence, a cell fate that is defined by an 
irreversible proliferative arrest, is known to induce a profound pro-inflammatory secretory 
pattern which alters the local microenvironment. Whether this cell cycle-related program also 
regulates the secretion pattern in terminally differentiated adipocytes is still poorly understood.  
1.5.1 Cellular senescence 
Senescent cells are in irreversible cell cycle arrest, accompanied by an active DNA damage 
response (DDR), high metabolic activity, and exhibite a senescence-associated secretory 
phenotype (SASP). Cellular senescence was first reported by Hayflick who described the 
phenomenon in proliferating cells in culture that gradually lost their capacity for division after 
50 serial passages, but still stayed alive for weeks in this a non-dividing state 174. This 
phenomenon is now known as ‘replicative senescence’, induced by constant telomere 
shortening through each round of cell division 175, and is an essential aspect of cellular aging. 
Meanwhile, a large body of recent studies has revealed several other mechanisms by which 
cells can become prematurely senescent. These include activation of oncogenes, oxidative 
stress, and DNA damaging agents, which lead to stress-induced premature senescence 176.  
 
Cellular senescence is implicated in both physiological and pathological processes 177. The 
most widely-studied role of senescence is in the context of cancer development, where 
senescence irreversibly blocks tumor cell proliferation and is viewed as an onco-suppressive 
safeguarding mechanism against tumorigenesis 178, 179. In mammalian embryonic development, 
senescence is essential for remodeling tissue and shaping organogenesis, such as in the 
development of the mesonephros and inner ear 180, 181. In wound healing, accumulation of 
senescent endothelial cells accelerates wound closure and reduces the size of the fibrotic scar 
182, 183. 
Depending on the biological context however, a senescent cell and its associated secretory 
phenotype can also be detrimental. In stress-induced premature senescence, the altered 
cellular function and secretory profile of cells has been associated with several aging-related 
diseases including osteoarthritis, atherosclerosis and Alzheimer’s disease 184-187. 
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Nevertheless, independent of aging, an increasing number of pathologies are being 
recognized as associated with premature cellular senescence, therefore, placing senescence 
as a central player in the cellular pathology of a variety of disorders, across many cell types 
and tissues 188. 
1.5.2 Characteristics of senescence 
Senescent cells are largely heterogeneous. The functional alterations that senescent cells 
exhibit, like cell size alteration or secretion profile, can partially also be present in other cellular 
states, and may diverge depending on the cell types or the stress triggers. Because of this 
complex phenotype there is still a lack of consensus on a senescent-specific profile of signature 
genes and proteins. Therefore, in order to precisely distinguish senescent cells, several 
hallmarks need to be considered together, including a DDR, cell cycle arrest, and the 
senescence associated secretion phenotype (SASP). 
 
1.5.2.1 DNA damage response 
It is widely believed that premature senescence is triggered by a persistent active DDR (Fig. 
6). DNA is sensitive to different types of stress such as telomere erosion and oxidative stress. 
The main consequence of stress is the accumulation of DNA single- and double-strand breaks 
(SSBs, DSBs) which, if left unrepaired, can lead to the accumulation of mutations and genome 
instability. To preserve genome integrity, cells respond to DNA damage by engaging a signal 
amplification cascade called DDR to block cell cycle progression and induce repair of the DNA 
lesion 189. If the damaged sites in proliferating cells are properly fixed, cell cycle will be quickly 
resumed. Otherwise, unrepaired damage can lead to a prolonged activation of the DDR which 
eventually translates into an irreversible cell cycle arrest (senescence) or apoptosis 190. 
 
After DSBs, the DDR is initiated by the recognition of the damage by a large protein complex, 
composed by Mre11, Rad50 and Nbs1, called the MRN complex. MRN recruits and activates 
the essential kinase ataxia telangiectasia-mutated (ATM) kinase, which efficiently 
phosphorylates the histone H2AX at Ser139 (called g-H2AX) 191. The loading of active ATM 
onto the damage site leads to the recruitment of additional ATM molecules, mediated by p53-
binding protein 1 (53BP1) and mediator of DNA-damage checkpoint 1 (MDC1), to strengthen 
the repair cascade and amplify the chromatin modification signals in a positive feedback loop. 
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The accumulation of repair factors (MRN complex, ATM, 53BP1 and MDC1) at the damage 
site generates a cytologically detectable structure called DNA damage foci (DDF) 192, 193. After 
the initial phosphorylation of g-H2AX, ATM phosphorylates the checkpoint kinases CHK1 and 
CHK2 within the foci, quickly followed by a distribution throughout the nucleus that helps 
spread the DDR signaling and further activate their downstream substrates, including p53 to 
block cell cycle progression 194, 195.  
 
 
Figure 6. Schematic representation of a DNA damage response (DDR) induced cell cycle arrest. 
ATM/ATR mediated DDR activates p53 pathway. The expression of two major CDK inhibitors, p16 
and p21, blocks cell cycle progression, leading to senescent cells arrest either at G1/S phase, or at G2 
phase that, via mitotic bypass, resulting in polyploidy in endoreplicated cells.  
 
The detection of DDF together with the expression of g-H2AX and p53 are often used as 
markers for the DDR and senescence (Fig. 6). However, it has been noted that the DDR is not 
always present in senescent cells 196. Moreover, oxidative stress-induced single-strand DNA 
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damage, which involves the activation of repair protein X-ray repair cross-complementing 
protein 1 and p16 expression, are also able to induce cellular senescence 197, 198.  
1.5.2.2 Cell cycle arrest 
Irreversible cell cycle arrest is one of the hallmarks of senescence. In vitro, a reduction in serial 
colony proliferation or decreased DNA synthesis measured by reduced EdU (5-ethynyl-20-
deoxyuridine) or BrdU (5-bromo-2-deoxyuridine) incorporation, are considered as signs of cell 
cycle arrest. While being technically easy in vitro, defining cell cycle arrest in vivo is not as 
straightforward. 
 
The DDR activates p53 which induces the transcription of the CDK inhibitor p21 (CDKN1A). 
p21 in turn blocks the interphase activity of CDKs, including CDK2, CDK4, and CDK6, thus 
preventing the phosphorylation of Rb to promote cell cycle arrest (Fig. 6 and ref. 199). 
Moreover, it was recently shown that the expression level of p21 is crucial to determine cell 
fate after DNA damage. Cancer cells with moderate DNA damage in G1 had a moderate p21 
state that could either evolve to low p21 expression and result in a proliferative phenotype or 
progress to high p21 expression and become senescent 200. Although p21 is suggested to be 
essential for initiating senescence, this study indicates that only using p21 as a cell cycle arrest 
marker is not sufficient. 
 
P16 is another Rb regulator that selectively inhibits the activity of CDK4 and CDK6, and blocks 
cell cycle progression. While p53/p21 are essential for initiating cell cycle arrest, p16 is 
recognized as important for maintaining the arrest, and thus enforcing the maintenance of 
senescence 201, 202. Independent of the p53 pathway, it has also been suggested that reactive 
oxygen species (ROS) trigger SSBs that upregulate the expression of p16 via p38 MAPK 
(mitogen-activated protein kinase) pathway, leading to cellular senescence 198, 202.  More 
importantly, specifically targeting p16 expression in mice can dramatically reduce senescent 
cell burden and result in marked improvements in health and extended lifespan 203-205. Taken 
together, numerous pieces of evidence emphasize the importance of p16, which is now widely 
used as a reliable senescence biomarker.  
 
G1 or G2 arrest? Previously, it was believed that senescence only arises from p21 or p16-
induced G0/G1 arrested cells. Such a conclusion was however challenged by evidence that 
there is an accumulation of polyploid mononuclear senescent cells after multiple rounds of 
  25 
division-induced proliferation exhaustion, which is accounted for by G2-arrested cells 206, 207. 
Not only limited to replicative senescence, others also described stress-induced p53 activation 
in G2 phase leading to senescence through mitosis bypass (Fig. 6 and ref. 208).  This process is 
mediated by p53-induced p21 activity, where p21 activates the anaphase-promoting 
complex/cyclosome (APC/CCDH1) to degrade mitotic cyclin B1, thus leading to either cell cycle 
exit or mitotic skipping, resulting in tetraploid (4N) mononucleated cells 208. Since the G1/S 
checkpoint is stronger than the G2/M transition, polypoid cells seem to further readapt to a G1-
like state, characterized by the accumulation of G1 cyclins (cyclin D1) 177, 209.  
 
1.5.2.3 Senescence associated secretory phenotype 
The senescence associated secretory phenotype (SASP) is one of the key hallmarks of 
senescence, and is composed of an array of cytokines, chemokines, pro-inflammatory factors 
and extracellular matrix remodeling factors. SASP-related factors are upregulated at a 
transcriptional level and dynamically released into the microenvironment, influencing multiple 
processes such as tissue remodeling, recruitment of immune response factors, induction of 
angiogenesis and fibrosis 210. Also, SASP transmitted signals can cause peripheral cells to 
senesce 203.  Pro-inflammatory cytokines (interleukin (IL)-1α, IL-1β, IL-6, and IL-8) and 
chemokines (MCP-1) are common SASP factors. However, most SASP factors have cell type-
specific characteristics. Even in the same cell type, different stress stimuli or time-course of 
senesce progression can induce a different secretory profile 211, 212, making the SASP very hard 
to define in a standard way across all cell types.   
 
The mechanism regulating the SASP is still not fully elucidated. Coppé et al. 213 suggested that 
ectopic expression of p16 and p21 induces cell cycle arrest and cellular senescence without a 
secretory phenotype, indicating that the two processes, cell cycle arrest and the SASP, can be 
separated in senescent cells. The main triggers inducing a SASP are more related to the 
presence of an active/ongoing DDR, followed by the activation of NF-κB 214. More recently, 
signaling pathways such as P38 MAPK, NOTCH, mTOR, as well as the mitochondrial 
NAD+/NADH ratio were suggested to participate in the regulation of the SASP 196, 215-217. 
Different mechanisms proposed to induce a SASP response might be triggered by different 
stimuli, which may also be linked to each other. Defining the target and SASP components in 
a specific cell type is necessary for understanding SASP related consequences. 
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1.5.2.4 Senescent cells morphology alteration  
Senescent cells exhibit multiple morphological alterations. Cell size is often increased and in 
some cases cells flatten when becoming senescent 218.  Senescent cells are associated with 
increased mitochondrial biogenesis, however they are dysfunctional and generate excessive 
amounts of ROS 219. Senescent cells contain a large amount of lysosomes, which can be 
detected by high b-galactosidase activity, through a senescence associated b-galactosidase 
assay (SABG). Although the β-galactosidase enzyme per se may not play a direct role in 
senescence, the SABG positivity has been established as a reliable biomarker of senescent cells 
215. Blagosklonny and coworkers summarize these morphological alterations as a 
‘hypertrophic’ phenotype, primarily induced by growth stimuli. Such growth stimuli are 
essential to push arrested cells to senesce, and is one of the predominant characteristics 
distinguishing senescence from quiescence, which is instead a transient type of cell cycle arrest 
220, 221.  
 
MTOR activation associates to a hypertrophic phenotype. It is well accepted that growth 
stimuli derived from excessive nutrition, hormones or growth factors can efficiently activate 
the AMPK and mTOR pathways. The major mTOR protein complex, mTORC1, is an essential 
element regulating cell growth and proliferation 222, 223. So far, the connection between mTOR 
activation and a senescence-related hypertrophic phenotype is still controversial 224, and the 
role of mTOR in senescence also needs clarification. However, it has been shown that mTOR 
activity is constitutively enhanced in senescent fibroblasts and other cell types 143, 225, 226. 
Overexpression of the mTORC1 substrate eIF-4E drives cellular senescence both in vitro and 
in vivo 227. Furthermore, rapamycin or metformin that inhibited the mTOR activation has been 
shown to extend life span, which is also associated with lower levels of senescence 228. Wang 
R et al. report that a low dose of rapamycin can significantly reduce SABG activity, as well as 
eliminate pro-inflammatory cytokine secretion in senescent fat tissue, without alteration of p16 
expression 228.  
 
In senescent cells, proliferative stimuli activate mTORC1, which stimulates S6K1 expression, 
and induces the expression of cyclin D1 226. Since cell cycle progression is blocked by the 
DDR, cyclin D1 expression accumulates and has been consistently observed in senescent cells 
229-231. Therefore, as a sign of high proliferative potential, high cyclin D1 has become a key 
factor in distinguishing senescence from quiescence 221. Still, more studies are needed to test 
whether reduced S6K1 activity can lead to a decrease in senescent cell burden. It is thus vital 
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to understand the mechanisms by which mTOR triggers senescence, to potentially identify 
valid targets to ameliorate senescence-associated tissue injury. 
 
 
Figure 7. Schematic of mechanisms inducing senescence. On one side, mitotic stimuli induce mTOR 
activation, pushing cell cycle entry. On the other side,  DDR activated by oxidative stress, oncogenic 
signaling, etc, blocks the cell cycle progression. Forces from both sides are essential for establishing a 
senescent state.  
1.5.3 Adipose tissue senescence 
Although the exact cell type(s) contributing to WAT senescence are debated, it has been shown 
that senescent cells accumulate in adipose tissue and that such accumulation is related to aging, 
obesity and diabetes 232. Studies in murine models have shown that increased ROS are one of 
the main causes of senescence. In response to increased ROS, the DDR activates the p53/p21 
pathway, promoting a senescent phenotype including high b-galactosidase activity and 
secretion of TNF-α and IL-6 233. The importance of DNA damage in the establishment of 
adipose tissue senescence was further investigated by the ablation of DNA polymerase η in 
mice, which led to extensive DNA damage followed by upregulated expression of ATM, p53 
and p21 234. Interestingly, with a normal chow diet, the poly η -/- mice already showed marked 
body fat gain, accompanied by accumulation of senescent cells and an increase in the SASP 
profile 234. These studies highlight the contribution of DNA damage to the development of 
adipose tissue senescence, obesity, tissue inflammation, and metabolic dysfunction in mice.  
 
In contrast, exercise or using antioxidant N-acetylcysteine (NAC) to decrease the amount of 
DNA damage has been shown to efficiently reduce the senescent cell burden in adipose tissue 
234, 235. In addition, the clearance of either p16-expressing cells or treating senescent apoptosis-
resistant cells with two senolytic drugs dasatinib (D) and quercetin (Q) increased adipogenic 
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potential, reduced adipocyte hypertrophy and macrophage infiltration, and largely improved 
glucose homeostasis and insulin sensitivity 204. These studies highlighted that cellular 
senescence is involved in adipose tissue regeneration, inflammation, and immune response, 
and is in turn associated with obesity and the complications of diabetes. 
 
1.5.3.1 Preadipocyte senescence 
Given the cellular heterogeneity of adipose tissue, it would be important to characterize the 
senescent phenotype at the cellular level, to understand the cell type specific senescence 
associated consequences. Amongst the various cell types in adipose tissue, it has been 
previously reported that preadipocytes can senesce, either via proliferative exhaustion in the 
aging process or stimulated by increased oxidative stress in obesity 203, 236, 237.  
 
The phenotype of senescent preadipocytes has been well characterized. Firstly, senescent 
preadipocytes, induced either by irradiation or serial rounds of replication, display a complex 
SASP profile. The array of cytokines shared by these two inducers include IL-1α, IL-1β, IL-6, 
IL-8, MCP-1, matrix metalloproteinase (MMP)-3, MMP-12, PAI-1, and TNF-α. These 
secreted SASP factors contribute to local inflammation and induce macrophage infiltration, in 
turn amplifying the immune response and consolidating inflammation at a whole adipose tissue 
level 238. Secondly, both the proliferation and differentiation potentials of preadipocytes are 
reduced in the senescent state 236-238. Moreover, through the pervasive effect of the SASP, 
senescent preadipocytes further impair the adipogenic capacity of surrounding progenitors and 
induce them to senesce 204, 238. Specific clearance of p16 positive senescent cells in obese mice 
restores adipogenesis, as demonstrated by upregulation of PPARγ or C/EBPα, subcutaneous 
adipose tissue expansion and improved insulin sensitivity 204. Interestingly, this study also 
showed that visceral adipocyte size decreased dramatically, indicating that p16-specific cell 
clearance may affect mature adipocytes as well  204.  
 
1.5.3.2 Mature adipocyte senescence 
Increased oxidative stress, inflammation, and the growth factor expression that occur in obesity 
are recognized as high risk factors causing cellular senescence 239. However, it is still poorly 
understood how mature adipocytes deal with accumulating environmental stress, or as non-
proliferating cells whether they can even senesce. 
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Previous studies have shown the upregulation of senescent markers at the whole adipose tissue 
level. Nevertheless, it is difficult to distinguish potentially senescent mature adipocytes from 
SVF cells by analyzing tissue sections. Two studies focused on isolated adipocytes: the first in 
obese mice induced by ectopic expression of agouti peptide and overeating 233; and the second 
in DNA polymerase η knockout mice 234. Both studies demonstrated that a DDR can be 
activated in mature adipocytes, evidenced by upregulation of ATM, p53, p21 and an increased 
inflammatory secretion profile including TNF-a, IL-6 and MCP-1. This therefore suggests 
senescent-like changes in adipocytes 233, 234.  
 
More recently, Vergoni et al. tracked the development of obesity in mice fed a high fat diet 
(HFD) and observed that the DDR was induced very early 240. Two weeks after initiating HFD, 
mature adipocytes exhibited high level of ROS, significant upregulation of the oxidative DNA 
damage marker 8-OHdG (8-hydroxy-2-deoxyguanosine), increased g-H2AX positive foci, and 
upregulated p53 and p21. Interestingly, despite the activation of the DDR at such an early stage 
of obesity, adipocyte insulin sensitivity and expression of GLUT mRNA was not altered after 
the 2 weeks of HFD stimulation. Compared to chow diet fed mice, HFD did not induce the 
upregulation of the inflammatory markers TNF-a, IL-6, IL1b and CCL2 after two weeks, as 
suggested previously by other studies 233, 234. Furthermore, the number of immune cells, 
including macrophages, neutrophils and lymphocytes, were also unchanged, and changes in 
these were only detected after 18 weeks of HFD. Unfortunately, analysis of the senescence-
related effects of long term HFD were missing in this study 240. The dissociation between the 
rapid DDR and delayed inflammatory secretion profile may be attributed to an insufficient 
induction of DNA damage, which is needed to be active for a long and persistent time to induce 
a final senescent state 214. Alternatively (and not exclusively), other factors may be involved 
that promote senescence in the late stages of obesity.  
 
Blaskolonny and others have demonstrated that merely a persistent DDR or the activation of 
p53 is not enough to induce cellular senescence, especially in cells with low proliferation 
potential such as quiescent cells (Chapter 1.5.2.4, and ref. 241, 242). To test whether this theory 
is also true in adipocytes and whether adipocytes acquire the proliferation potential that leads 
them to senesce, in Paper III, we demonstrated that mature adipocytes exhibited a cell cycle 
profile driven by hyperinsulinemia, which is an essential reason causing adipocyte to senesce. 
The data we provided hopefully can bring new insights into the mechanisms involved in 
adipocyte dysfunction in obesity and related diseases.   
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2 AIMS OF THE THESIS 
 
The general aim of this thesis is to understand the mechanisms underlying adipose tissue 
dysfunction in obesity. Particularly, I have focused my thesis study on human mature 
adipocytes to understand how these cells adapt to cellular hypertrophy and why they alter their 
function from being a safe fat storage pool to a risk factor for type 2 diabetes. Given the 
challenging nature of adipose tissue, I aimed to develop and optimize methods and techniques 
to be able to better study human mature adipocytes. Lastly, I also wished to identify any 
essential mechanism behind adipocyte dysfunction.  
 
Specific aims: 
1. To develop a flow cytometry-based method to analyze mature adipocytes in a high 
throughput manner and answer the question about how human adipocyte ADRB2 expression 
levels are affected by obesity (Paper I). 
 
2. To establish an in vitro system for culturing human primary adipocytes without losing 
cellular specificity and investigate whether it is possible to transdifferentiate human adipocytes 
into brown-like adipocytes (Paper II). 
 
3. To characterize the effects of obesity and hyperinsulinemia on adipocyte phenotypic 
alterations in relation to cell cycle entry and in relation to cellular senescence (Paper III). 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Adipocytes exhibit large cellular variations in response to high nutrient overloading and are, as 
such, recognized as a complex heterogeneous cell type 243, 244. Even from a single depot, based 
on preadipocyte lineages, adipocytes can be divided into several subgroups, which exhibit 
distinct metabolic properties and responses to stimuli such as insulin 45. Future treatments 
against obesity may greatly benefit from a precision medicine approach that specifically targets 
dysfunctional adipocytes. However, the molecular heterogeneity of adipocytes remains 
unclear. Flow cytometry is a powerful tool that can analyze and sort single cells in a high 
throughput manner and is widely used for understanding the molecular mechanisms of cellular 
heterogeneity. Unfortunately, the morphological characteristics of mature adipocytes (lipid-
filled, large, and fragile) make the use of flow cytometry very challenging.  
 
Although several adipocyte flow cytometric methods have previously been described 245-247, 
we observed that mouse adipocytes, genetically labelled with tdTomato, were undetectable 
using these reported methods, which instead mainly captured tdTomato negative SVF cells 
(Fig. 1 in Paper I). We therefore developed a flow cytometric strategy that allowed us to 
analyze and sort mature adipocytes with high sensitivity and throughput (Fig. 2). The new flow 
cytometric approach was found by modifying several critical settings: inserting a neutral 
density (ND) filter to reduce the general forward scatter (FSC) intensity and bring the high FSC 
adipocytes into a detectable range; increasing the FSC threshold to reduce the noise caused by 
small debris and bringing large adipocytes into focus; and the use of an in-tube stirring system 
to adequately mix the cell suspension and deliver buoyant adipocytes into the sampler. With 
the newly developed strategy, we were able to show that tdTomato positive adipocytes appear 
as a large, easily detected cluster, allowing for subsequent analysis and sorting (Fig. 3). The 
described critical settings are not only feasible for adipocytes, but may also be used in the 
detection of other large or fragile particles by flow cytometry. 
 
We further observed that side scatter (SSC), not FSC, provided an approximation of adipocyte 
size (Fig. 4). This allowed us to efficiently sort small and large adipocytes based on their SSC 
characteristics, without involving any steps of fixation or staining with fluorescent dyes, which 
constituted a significant advantage for subsequent downstream molecular applications. The 
size-based sorting approach can greatly facilitate studies which investigate adipocyte 
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hypertrophy and heterogeneity. Furthermore, the improved flow cytometry strategy can be 
used in combination with an antibody staining step for adipocytes. As a proof of concept, we 
tested UCP1 immunostaining on mouse adipocytes, and specifically sorted UCP1+ adipocytes 
from brown adipose tissue and β3-adrenergic agonist (CL 316,243) stimulated subcutaneous 
white adipose tissue (Fig. 6). Thus, we demonstrated the rapid and straightforward detection 
of adipocyte subpopulations, which in addition to investigating the browning potential of 
various treatments on white adipocytes, can be equally useful for any study that requires high-
throughput single cell adipocyte information. 
 
The expression density of ADRB2 on human adipocytes is essential for inducing adipocyte 
lipolysis, however, its expression pattern on human adipocytes remains not fully clear. 
Therefore, we sought to investigate the expression of ADRB2 in human adipocytes using our 
newly established flow cytometry method, testing two different antibodies against ADRB2. 
We observed a decrease in ADRB2 expression in adipocytes from obese insulin-resistant 
individuals (Fig. 7A-D), a result that was consistent with previous reports 30. However, the 
flow cytometry data revealed that the reduced ADRB2 level is not due to a general decrease of 
protein level in every adipocyte, but instead can be explained by a heterogeneous distribution 
of ADRB2 expression in different subgroups of adipocytes, namely, we observed two distinct 
adipocyte clusters: an ADRB2 negative cluster and an ADRB2 positive one (Fig. 7E). The 
percentage of ADRB2 negative adipocytes increased dramatically in the insulin resistant 
individuals and revealed a heterogeneous loss of ADRB2 signals. These results allowed us to 
speculate that the reduced rate of stimulated lipolysis in obesity may be due to an increase in a 
subpopulation of dysfunctional adipocytes (lacking the main lipolytic receptor, ADRB2), while 
the rest of the adipocytes remain healthy 107. This evidence also suggested that specifically 
targeting unhealthy adipocytes may be considered a future therapeutic strategy to treat insulin 
resistance. 
 
In conclusion, our study confers new technological possibilities for high-throughput analysis 
and sorting of human and mouse adipocytes. Our flow cytometry approach represents a 
significant improvement in the toolbox available to explore the biological mechanisms 
underlying adipocyte hypertrophy, heterogeneity, and browning. Given the relative simplicity 
of the method, we are positive that it can be further applied to the study of other questions in 
the field of adipose tissue biology and contribute to the understanding of obesity-related 
pathological mechanisms.  
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3.2 PAPER II 
Brown and beige adipocytes consume stored lipids and glucose through thermogenic energy 
expenditure. Inducing white adipocytes to express UCP1 or transform to a thermogenic brown-
like phenotype has been shown to be able to decrease body weight, promote insulin sensitivity 
and reverse metabolic disorders in a large body of animal studies (reviewed in ref. 248). White 
adipocyte browning is therefore becoming an attractive therapeutic avenue for obesity and type 
2 diabetes treatment. However, translating the studies from animal models to human adipocytes 
has been obstructed, partly due to the limitations of in vivo human studies, but also because of 
the lack of a reliable in vitro model for testing browning mechanisms in human adipocytes.  
 
Most studies on adipocytes have relied on the in vitro differentiation of pre-adipocytes into 
mature adipocytes, however this presents a series of limitations. Most importantly, in vitro 
differentiated adipocytes are small and multilocular, missing the crucial unilocular and 
spherical characteristics of mature adipocytes.  
 
In Paper II we developed a method to culture mature adipocytes that keep buoyant adipocytes 
floating while aggregating underneath a transwell membrane, termed “Membrane Mature 
Adipocyte Aggregate Cultures”, MAAC (Fig. 1A in Paper II). This setup provides ample cell-
cell contact and mimics the in vivo environment. We showed that the MAAC successfully 
maintained primary adipocyte properties and metabolic functions. Both mouse and human 
MAAC-cultured adipocytes, compared to non-cultured controls, preserved the expression 
levels of a number of adipogenic transcripts, including PPARG, FABP4, ADIPOQ, LIPE, and 
LPL (Fig. 1B, C). Further, by using unbiased mRNA sequencing, we compared transcriptional 
differences of adipocytes cultured using MAAC, floating cultures, traditional progenitor 
differentiation-based cultures, and transplanted tissue piece cultures (Fig. 2). The sequencing 
results revealed that adipocytes in MAAC displayed the highest similarity to non-cultured in 
vivo controls. We observed that cells from currently used methods of in vitro differentiated 
adipocytes also showed a transcript profile similar to the non-cultured controls, despite the 
obvious differences in cell size and multilocular lipid droplets. Furthermore, we also showed 
that MAAC can successfully preserve fat depot specific genetic expression patterns even after 
14 days of culture (Fig. 3). Moreover, mature adipocyte morphology, adipocyte functions such 
as lipogenesis and lipolysis, as well as the response to insulin and several pharmacological 
stimuli were also maintained after culturing adipocytes for two weeks using MAAC (Fig. 4). 
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Altogether, our data demonstrates that using MAACs to study primary adipocytes is highly 
advantageous compared to existing methods in the field.  
 
It is known that cold stimuli can induce the generation of brown-like adipocytes in rodent white 
adipose tissue. In vitro differentiated human pre-adipocytes stimulated by rosiglitazone or other 
PPARγ enhancers have also been shown to acquire a brown adipocyte-like phenotype. 
However, differentiated adipocyte model involves using a differentiation cocktail that contains 
non-physiological levels of hormones which may interfere with the induction of browning. 
Even in mice, it is still under debate whether beige adipocytes arise from the differentiation of 
a separate population of pre-adipocytes, or through the transdifferentiation of mature cells 249, 
250. Furthermore, it remains unknown whether transdifferentiating primary human mature 
adipocytes into brown-like cells is possible. To answer this question, we first transduced human 
mature adipocytes with adenovirus-containing PGC-1α (PPARγ coactivator 1α), the master 
mitochondria biogenesis regulator. Using MAAC, we showed that both overexpression of 
PGC-1α and rosiglitazone could successfully induce the expression of UCP1 in human 
subcutaneous white adipocytes (Fig. 6). Therefore, we confirmed that human adipocytes are 
also able to acquire a brown-like phenotype which argues against previous studies claiming 
that subcutaneous white adipocytes do not have the capacity to brown 5. Whether different 
adipose depots in humans harbour varying potentials for browning needs to be investigated, 
likely providing new insight as to the mechanisms of functional transition in human adipocytes. 
 
Taken together, in Paper II, we established a mature adipocyte culture system, MAAC, that 
faithfully maintains adipocyte identity and function for a prolonged period of time. The MAAC 
can be widely exploited in a variety of in vitro studies of mature adipocytes. We demonstrated 
its potential by investigating a fundamental question of adipocyte biology, namely the capacity 
of white adipocytes to brown; however, MAAC can also be used in more direct applications 
like the development of high-throughput drug screens to improve obesity treatments. Co-
culturing and looking at the interplay between various cell types and adipocyte is also another 
powerful application of the MAAC system. 
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3.3 PAPER III 
During the establishment of obesity, nutrient excess remodels adipocytes, causing adipocyte 
hypertrophy. In addition to the enlarged capacity for storing fat, hypertrophic adipocytes also 
secrete various pro-inflammatory cytokines that attract immune cells and impair the insulin 
signaling pathway. Despite the important metabolic role of adipocytes, the mechanism 
underlying adipocyte dysfunction in obesity/metabolic disease has not been fully elucidated.  
 
In order to better understand the regulation of adipocyte dysfunction, we performed mRNA 
sequencing on human adipocytes collected from non-obese, obese normo-insulinemic, and 
obese hyperinsulinemic individuals. The enriched pathway analysis surprisingly highlighted 
differences in cell cycle and senescence-related transcripts between the patient groups, 
including expression of cyclins, replication proteins, and replication-dependent histones in 
adipocytes (Fig. 1b, c in Paper III). Furthermore, immunocytochemistry staining of freshly 
isolated adipocytes revealed that human adipocytes express multiple canonical cell cycle 
markers such as Ki-67, Anillin, PCNA (proliferating cell nuclear antigen), and pHH3, but also 
express cyclins, including D1, E1, and A2 (Fig. 1d, e and extended data Fig. 1). This data 
strongly indicated a cell cycle re-entry profile in mature adipocytes, which was confirmed by 
in vitro data showing that cultured human primary adipocytes actively incorporate EdU, 
demonstrating de novo DNA synthesis and progression through S-phase (Fig. 3). 
Despite the solid evidence supporting cell cycle re-entry, human mature adipocytes do not go 
through mitosis or cell division as was previously proposed in mouse brown fat tissue 173, 251. 
Firstly, M phase-related transcripts such as FOXM1, AURKB, CDK1 were not expressed in 
adipocytes(Fig. 1c). Secondly, despite the expression of mitotic cyclin B1, its uniquely 
cytoplasmic location did not support progression into mitosis. Similarly, Anillin and pHH3 
were also expressed in adipocytes in a G2-phase fashion and did not show a mitotic pattern 
(Extended data Fig. 1f-h). This led us to propose that human adipocytes can re-enter cell 
cycle, but are unable to undergo mitosis or cell division. This phenomenon, referred as 
endoreplication, is known to happen in large cells, but has not been reported for mammalian 
adipocytes.  Cells that have undergone endoreplication are usually polyploid and contain large 
nuclei with increased DNA content, allowing cells to enhance their protein production, 
enabling them to adapt to an increased cell size 161. 
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We also observed that hypertrophic adipocytes contained larger nuclei than small adipocytes. 
The volume of a large adipocyte nucleus was two-fold that of a small adipocyte nucleus from 
the same individual (data not shown). It is established that increased nuclear size often 
associates with increased genomic content 162. Interestingly, in our in vitro studies we observed 
that EdU positive adipocytes, namely, cells that had undergone a new round of DNA synthesis, 
clearly possessed larger nuclei. In vivo, we found that Cyclin D or cyclin A positive adipocytes 
tended to have larger nuclei than their negative counterparts (Fig. 2d). Altogether, the data 
indicated that a proportion of nuclei may contain high amounts of DNA. Still, further studies 
are needed to determine the exact ploidy in adipocytes to better understand the cell cycle re-
entry program relating to adipocyte hypertrophy.  
Importantly, adipocyte cell cycle entry was not an accidental phenomenon. We discovered that 
the expression levels of cyclin D1, A2, and pHH3, as well as nuclear size, displayed significant 
positive correlations with the levels of C-peptide (insulin secretion) and insulin resistance (Fig. 
2c). This suggests that hyperinsulinemic obese individuals have more adipocytes committed to 
re-enter the cell cycle than subjects with normal insulin levels or non-obese individuals. 
Consistently, the addition of insulin to cultured adipocytes significantly increased EdU 
incorporation. On the other hand, depletion of insulin by using charcoal treated serum lowered 
the number of adipocytes undergoing DNA synthesis (Fig. 3). Together, this data suggests that 
adipocyte cell cycle re-entry is driven by serum insulin.  
We also quantified the expression of the cell cycle marker Ki-67 in adipocytes. Contrary to 
those of cyclins, Ki-67 levels were lower in adipocytes from hyperinsulinemic individuals, 
indicating a pattern of cell cycle arrest (Fig. 4a). We found that this cell cycle arrest was 
associated with cellular senescence, a phenomenon not commonly described for postmitotic 
cells. Adipocytes displayed several senescence markers, including increased β-galactosidase 
activity, reduced nuclear expression of HMGB1 (high mobility group box protein 1), increased 
p16, p21 and γ-H2AX, as well as upregulated transcripts that associate with a senescence 
related secretion phenotype, including IL6 and CXCL8 (IL-8) (Fig. 5). Interestingly, adipocyte 
senescence was not correlated with aging, but rather mostly occurred in hyperinsulinemic obese 
individuals.  
The finding that insulin can induce cell cycle entry, but also associates with adipocyte 
senescence may seem paradoxical. As the mTOR pathway has been suggested to be involved 
in both of these processes, we used the AMPK-activator metformin, which is currently the most 
  37 
prescribed treatment for type 2 diabetes, to inhibit mTOR activation in human adipocytes. 
Given together with insulin, metformin completely blocked adipocyte cell cycle re-entry, as 
well as prevented adipocyte senescence (Fig. 6g-i). These results suggest that the mTOR 
pathway mediates adipocyte cell cycle entry, which is necessary for the establishment of 
senescence. Next, we introduced a CDK4/6 inhibitor, palbociclib, which is used in the clinic to 
treat amongst other cancers, breast cancer, to insulin-stimulated adipocytes. Palbocilib induced 
a distinctive cell cycle arrest but, in contrast to metformin, dramatically increased adipocyte 
senescence, indicating that blocking cell cycle downstream of mTOR signalling led to 
senescence. As expected, metformin prevented adipocyte senescence, resulting in a  profound 
decrease of the SASP, including IL-6, IL-8, IL-1β, MCP-1 and TNF-α. Interestingly, 
Palbociclib-induced adipocyte senescence did not affect adipocyte secretion factors, which 
may represent a treatment time not long enough to induce changes. Taken together, the data 
demonstrate that hyperinsulinemia can drive adipocyte cell cycle entry through activation of 
mTOR signaling, which along with cellular stress can facilitate the development of cellular 
senescence.  
Although adipocytes isolated from hyperinsulinemic individuals develop insulin resistance 
with impaired glucose uptake, the insulin signaling in the cells is not entirely blocked, as 
previously suggested in animal studies 99, 146. In human adipocytes, we observed that the 
insulin-induced AKT phosphorylation was preserved in hyperinsulinemic individuals, 
supporting the existence of an intact insulin signaling pathway in these subjects (Fig. 3i). 
During the establishment of obesity, chronic high levels of insulin may thus activate the mTOR 
pathway through the selectively preserved insulin signaling pathways and stimulate adipocyte 
cell cycle re-entry.  
Finally, although the presence of a mitotic stimuli such as insulin is a prerequisite for 
stimulating adipocyte cell cycle re-entry, the presence of a cellular block is also required for 
the induction of senescence. Whilst metformin prevented cell cycle entry, palbociclib only 
affected cell cycle progression, further supporting the notion that cell cycle blockers such as 
p16 and p21 activate a senescenct program in mature human adipocytes. In obesity, it has been 
shown that the DDR can be stimulated by a high amounts of ROS, which are also associated 
with high adipocyte senescence 233. It is therefore tempting to speculate that the persistent DDR 
in adipocytes that may occur in obese individuals can block the hyperinsulinemia-induced cell 
cycle re-entry, eventually resulting in senescence. Still, further experiments are required to 
support this hypothesis. 
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In conclusion, in Paper III, we discovered that human mature adipocytes display a cell cycle 
re-entry program in response to hyperinsulinemia, characterized by enlarged nuclear and cell 
size. Cell cycle re-entry is an essential step leading to cellular senescence, which then induces 
the secretion of inflammatory factors that exacerbates adipose tissue inflammation. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Adipocyte dysfunction is associated with metabolic disorders like insulin resistance and 
hyperlipidemia, are direct causes for type 2 diabetes and cardiovascular disease. These 
considerations bring adipocytes to the center of the mechanisms regulating whole-body 
metabolic homeostasis. Studies in this thesis provide new methods and aspects in 
understanding adipocyte biology, but also open many new questions to be answered.  
In Paper I, the flow cytometry method we developed offers a new option to analyze adipocytes 
in a highly effective way, which could greatly benefit investigations seeking to understand 
adipocyte heterogeneity. As we found the heterogeneous expression pattern of ADRB2 
expression, it would be interesting to further investigate other aspects related to the ADRB2-
negative adipocyte population. Do ADRB2-negative cells display enlarged cell size, reduced 
insulin sensitivity or other dysregulated characteristics? What are the mechanisms that mediate 
the downregulation of ADRB2 in a specific subgroup of cells? Is there a heterogeneous 
expression pattern of other molecules regulating lipolysis or insulin sensitivity in adipocytes as 
well? Is there functional heterogeneity between adipocytes or does one particular cluster of 
adipocytes contain all the dysregulated functions? Answers to these questions will hopefully 
provide new insights into adipocyte biology. 
In Paper II, we present a novel cell culture method for adipocytes, allowing us to directly 
modulate human or mouse mature adipocytes in vitro, whilst maintaining improved ex vivo 
adipocyte characteristics. This new model can hopefully help to translate a large amount of 
animal study results into human adipocytes, including future studies on inducing human 
adipocyte browning, for instance, comparing the adipose depot differences in the ability of 
adipocyte browning. Investigating adipocyte crosstalk with other cells types, such as 
macrophages or endothelial cells could also greatly benefit from the MAAC co-culture 
possibilities. Furthermore, it would be interesting to use the MAAC for high throughput 
compound screening experiments and discover targets that regulate adipocyte function.  
In Paper III, our finding of cell cycle re-entry and senescence in human mature adipocytes 
opens up a whole new perspective in adipocyte biology. Considering adipocytes as post-mitotic 
cells, unable to re-activate a cell cycle program has been a cornerstone of adipocyte biology. 
We provide data that challenges this and prompts one to reconsider current views of adipocyte 
physiology. Additional experiments investigating the ploidy of adipocytes and how adipocytes 
 40 
respond to obesity and hyperinsulinemia at a cell size/DNA level are important next steps. 
Additionally, it is still not clear which parts of the insulin signaling pathway are preserved in 
hyperinsulinemic adipose tissue, and which ones may be overactivated. Further studies are 
required to investigate the role of the mTOR pathway in adipocyte cell cycle re-entry and 
senescence. Lastly, research needs to continue on adipocyte senescence. How is senescence 
initiated, is it also in human adipocytes due to a DDR? We still do not know the complete 
extent of the functional alterations in senescent adipocytes. For example, does senescence 
affect normal adipocyte lipid handling, such as lipolysis or lipogenesis? How do senescent 
adipocytes communicate with immune cells? Are senescent cells more resistant to apoptosis? 
Sorting senescent adipocytes to investigate these functional changes could be one way forward 
to better understand the consequences of senescence in mature, human adipocytes.  
In conclusion, this thesis work provides a novel primary adipocyte culture model and a flow 
cytometric analysis approach that are useful tools for the study of mature adipocytes. We 
discovered and characterized human adipocyte cell cycle re-entry and senescence, shedding 
new light on the mechanisms inducing adipocyte dysfunction, and thus contributing to finding 
future therapeutic strategies for combating obesity-related metabolic disorders. 
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